![]() VIARTIS
|
||||||||
PARKINSON'S DISEASE NEWS |
||||||||
|
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].
12th February 2017 - News release L-DOPA INHALER IMPROVES PARKINSON'S DISEASE
The L-dopa inhaler CVT-301 significantly improved Parkinson's Disease symptoms in clinical trials. CVT-301 utilizes ARCUS� for inhaled therapeutics. CVT-301 is designed to deliver a precise dose of a dry powder formulation of L-dopa. Inhaled treatments enter the body through the lungs and then reach the brain far more quickly, by bypassing the digestive system. For more information go to dementia : Arcus
In a previous study the effect of the L-dopa
inhaler was around 10 minutes, which is far quicker than the effect of
L-dopa when it is taken orally. This would enable the widespread additional
use of the L-dopa inhaler for when a quicker effect is required. Acorda said
it will file an NDA with the FDA (the U.S. medicines authority) by the end
of the second quarter, and a marketing authorisation application with the
European Medicines Agency by the end of 2017, pending additional data
analyses. News release :
News release
For more news go to
Parkinson's Disease News
|
|
||||||
![]() |
||||||||
�2006-2017 Viartis | ||||||||
2017-02-12 17:13:08 | ||||||||
[email protected] |